$100 billion year in sights, pharma superstar Pfizer scales new heights

Continuing its extraordinary ascent, the world’s largest pharmaceutical firm, Pfizer (NYSE: PFE), reported solid financial results in the third quarter of 2022, with revenues of $22.6 billion.

While revenues declined 2% on an operational basis, a reflection of the extreme demand for its coronavirus products last year, the outcome was still well over a billion dollars above the FT consensus forecast of $21 billion.

Following Generally Accepted Accounting Principles (GAAP), Pfizer reported earnings per share of $1.78, a 40% boost on the same period of 2021.